

## 原著論文

2022年（令和4年）

\*は他教室への協力

1.Hongo T, Yamamoto H, Tanabe M, Yasumatsu R, Kuga R, Miyazaki Y, Jiromaru R, Hashimoto K, Tateishi Y, Sonoda KH, Nakagawa T, Oda Y.

High-risk HPV-related squamous cell carcinoma in the conjunctiva and lacrimal sac: clinicopathologic characteristics and diagnostic utility of p16 and Rb immunohistochemistry.

Am J Surg Pathol. 2022 Jul;46(7):977-987

2.Hori Y, Yamamoto H, Kawatoko S, Nozaki Y, Torisu T, Kato K, Koga Y, Miyoshi H, Ohshima K, Tateishi Y, Nakamura S, Kitazono T, Oda Y.

Lymphoid and myeloid proliferative disorders associated with inflammatory bowel disease: a clinicopathological study of 15 cases.

Hum Pathol. 2022 Feb;120:88-98

3.Ishihara S, Yamamoto H, Iwasaki T, Toda Y, Yamamoto T, Yoshimoto M, Ito Y, Susuki Y, Kawaguchi K, Kinoshita I, Yamada Y, Kohashi K, Fujiwara T, Setsu N, Endo M, Matsumoto Y, Kakuda Y, Nakashima Y, Oda Y.

Histological and immunohistochemical features and genetic alterations in the malignant progression of giant cell tumor of bone: a possible association with TP53 mutation and loss of H3K27 trimethylation.

Mod Pathol. 2022 May;35(5):640-648

4.Iwasaki T, Hayashi K, Matsushita M, Nonaka D, Kohashi K, Kuwamoto S, Umekita Y, Oda Y.

Merkel cell polyomavirus-negative Merkel cell carcinoma is associated with JAK-STAT and MEK-ERK pathway activation.

Cancer Sci. 2022 Jan;113(1):251-260

5.Kiyozawa D, Kohashi K, Takamatsu D, Iwasaki T, Shibata D, Tomonaga T, Tateishi Y, Eto M, Kinjo M, Nishiyama K, Taguchi K, Oshiro Y, Kuboyama Y, Furuya M, Oda Y.

Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma.

Hum Pathol. 2022 Jun;124:36-44

6.Magarifuchi N, Yamada Y, Oishi Y, Kato K, Taguchi K, Oda Y.

Neuroectodermal rosettes in immature teratomas are not the counterpart of embryonal tumours with multilayered rosettes.

Anticancer Res. 2022 Sep;42(9):4337-4344

7.Mori T, Yamada Y, Kinoshita I, Kohashi K, Yamamoto H, Ito Y, Susuki Y, Kawaguchi K, Nakashima Y, Oda Y.

Clinicopathological and histopathological review of dedifferentiated liposarcoma: a comprehensive study of 123 primary tumours.

Histopathology. 2022 Feb;80(3):538-557

8.Oda Y, Tanaka K, Hirose T, Hasegawa T, Hiruta N, Hisaoka M, Yoshimoto M, Otsuka H, Bekki H, Ishii T, Endo M, Kunisada T, Hiruma T, Tsuchiya H, Katagiri H, Matsumoto Y, Kawai A, Nakayama R, Kawashima H, Takenaka S, Emori M, Watanuki M, Yoshida Y, Okamoto T, Mizusawa J, Fukuda H, Ozaki T, Iwamoto Y, Nojima T.

Standardization of evaluation method and prognostic significance of histological response to preoperative chemotherapy in high-grade non-round cell soft tissue sarcomas.

BMC Cancer. 2022 Jan;22(1):94

9.Ozono K, Onishi H, Iwamoto N, Nakamura K, Miyoshi K, Nakamura M, Oda Y.

Tropomyosin-related kinase B is potentially a biomarker of prognosis and therapeutic target for malignant thymic epithelial tumors.

Anticancer Res. 2022 Aug;42(8):3779-3787

10.Sakihama K, Koga Y, Yamamoto T, Shimada Y, Yamada Y, Kawata J, Shindo K, Nakamura M, Oda Y. RNF43 as a predictor of malignant transformation of pancreatic mucinous cystic neoplasm.

Virchows Arch. 2022 Jun;480(6):1189-1199

11.Sasaki T, Kohashi K, Kawatoko S, Ihara E, Oki E, Nakamura M, Ogawa Y, Oda Y.

Tumor progression by epithelial-mesenchymal transition in ARID1A- and SMARCA4-aberrant solid-type poorly differentiated gastric adenocarcinoma.

Virchows Arch. 2022 May;480(5):1063-1075

12.Yamada Y, Kinoshita I, Miyazaki Y, Tateishi Y, Kuboyama Y, Iwasaki T, Kohashi K, Yamamoto H, Ishihara S, Toda Y, Ito Y, Susuki Y, Kawaguchi K, Hashisako M, Yamada-Nozaki Y, Kiyozawa D, Mori T, Yamamoto T, Tsuchihashi K, Kuriwaki K, Mukai M, Kawai M, Suzuki K, Nishimura H, Bando K, Masumoto J, Fukushima M, Motoshita J, Mori H, Shiose A, Oda Y.

Myxoid type and non-myxoid type of intimal sarcoma in large vessels and heart: review of histological and genetic profiles of 20 cases.

Virchows Arch. 2022 Apr;480(4):919-925

13.Yamada Y, Kohashi K, Kinoshita I, Yamamoto H, Iwasaki T, Yoshimoto M, Ishihara S, Toda Y, Ito Y, Kuma Y, Yamada-Nozaki Y, Koga Y, Hashisako M, Kiyozawa D, Kitahara D, Narutomi F, Kuboyama Y, Nakamura T, Inoue T, Mukai M, Honda Y, Toyokawa G, Tsuchihashi K, Fushimi F, Taguchi K, Nishiyama K, Tamiya S, Oshiro Y, Furue M, Nakashima Y, Suzuki S, Iwaki T, Oda Y.

Histological background of dedifferentiated solitary fibrous tumour.

J Clin Pathol. 2022 Jun;75(6):397-403

14.Yamamoto T, Kohashi K, Yamada Y, Kawata J, Sakihama K, Matsuda R, Koga Y, Aishima S, Nakamura M, Oda Y.

Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma.

J Cancer Res Clin Oncol. 2022 Nov;148(11):2945-2957

15.\*Fukumura M, Ishibashi K, Nakaguro M, Nagao T, Saida K, Urano M, Tanigawa M, Hirai H, Yagyuu T, Kikuchi K, Yada N, Sugita Y, Miyabe M, Hasegawa S, Goto M, Yamamoto H, Ohuchi T, Kusafuka K, Ogawa I, Suzuki H, Notohara K, Shimoda M, Tada Y, Kirita T, Takata T, Morinaga S, Maeda H, Warnakulasuriya S, Miyabe S, Nagao T.

Salivary gland polymorphous adenocarcinoma: clinicopathological features and gene alterations in 36 Japanese patients.

J Oral Pathol Med. 2022 Sep;51(8):710-720

16.\*Guan W, Nakata K, Sagara A, Iwamoto C, Endo S, Matsuda R, Matsumoto S, Ikenaga N, Shindo K, Moriyama T, Onishi H, Ohuchida K, Oda Y, Nakamura M.

ERAP2 is a novel target involved in autophagy and activation of pancreatic stellate cells via UPR signaling pathway.

Pancreatology. 2022 Jan;22(1):9-19

17.\*Hamasaki H, Shijo M, Nakamura A, Honda H, Yamada Y, Oda Y, Ohara T, Ninomiya T, Iwaki T.

Concurrent cardiac transthyretin and brain  $\beta$  amyloid accumulation among the older adults: the Hisayama study.

Brain Pathol. 2022 Jan;32(1):e13014

18.\*Hashimoto K, Yasumatsu R, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T.

Treatment efficacy of PD-1 inhibitor therapy in patients with recurrent and/or metastatic salivary gland carcinoma.

Anticancer Res. 2022 Feb;42(2):981-989

19.\*Higuchi K, Urano M, Akiba J, Nogami M, Hirata Y, Zukeran Y, Moriyoshi K, Tada Y, Fukushima M, Obayashi M, Sakamoto S, Kuraoka K, Kira K, Kawahara A, Kato T, Tanigawa M, Nakaguro M, Yamamoto H, Nagao T.

A multi-institutional study of salivary gland cytopathology: Application of the milan system for reporting salivary gland cytopathology in Japan.

Cancer Cytopathol. 2022 Jan;130(1):30-40

20.\*Ibusuki R, Yoneshima Y, Hashisako M, Matsuo N, Harada T, Tsuchiya-Kawano Y, Kishimoto J, Ota K, Shiraishi Y, Iwama E, Tanaka K, Oda Y, Okamoto I.

Association of thyroid transcription factor-1 (TTF-1) expression with efficacy of PD-1/PD-L1 inhibitors plus pemetrexed and platinum chemotherapy in advanced non-squamous non-small cell lung cancer.

Transl Lung Cancer Res. 2022 Nov;11(11):2208-2215

21.\*Irie T, Yoshii D, Komohara Y, Fujiwara Y, Kadohisa M, Honda M, Suzu S, Matsuura T, Kohashi K, Oda Y, Hibi T.

IL-34 in hepatoblastoma cells potentially promote tumor progression via autocrine and paracrine mechanisms.

Cancer Med. 2022 Mar;11(6):1441-1453

22.\*Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Yugawa K, Shimokawa M, Shimagaki T, Wang H, Kurihara T, Kitamura Y, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M.

Impact of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma: cancer metabolism and immune status.

Hepatol Commun. 2022 Apr;6(4):665-678

23.\*Ito T, Hashimoto H, Tanaka Y, Tanegashima K, Murata M, Ichiki T, Iwasaki T, Oda Y, Kaku-Ito Y. TROP2 expression in sebaceous and sweat gland carcinoma.

J Clin Med. 2022 Jan;11(3):607

24.\*Ito T, Hashimoto H, Tanaka Y, Tanegashima K, Murata M, Oda Y, Kaku-Ito Y.

NECTIN4 expression in sebaceous and sweat gland carcinoma.

Eur J Dermatol. 2022 Apr;32(2):181-186

25.\*Jiromaru R, Yasumatsu R, Yamamoto H, Kuga R, Hongo T, Nakano T, Manako T, Hashimoto K, Wakasaki T, Matsuo M, Nakagawa T.

A clinical analysis of oropharyngeal squamous cell carcinoma: a single-institution's experience.

Eur Arch Otorhinolaryngol. 2022 Jul;279(7):3717-3725

26.\*Kamori T, Oki E, Shimada Y, Hu Q, Hisamatsu Y, Ando K, Shimokawa M, Wakai T, Oda Y, Mori M.

The effects of ARID1A mutations on colorectal cancer and associations with PD-L1 expression by stromal cells.

Cancer Rep (Hoboken). 2022 Jan;5(1):e1420

27.\*Kawakubo N, Takemoto J, Koga Y, Hino Y, Tamaki A, Kohashi K, Ono H, Oda Y, Ohga S, Tajiri T.

The utility of core-needle tumor biopsy for pediatric patients.

Pediatr Int. 2022 Jan;64(1):e15228

28.\*Kikuchi K, Togao O, Yamashita K, Momosaka D, Kikuchi Y, Kuga D, Hata N, Mizoguchi M, Yamamoto H, Iwaki T, Hiwatashi A, Ishigami K.

Quantitative relaxometry using synthetic MRI could be better than T2-FLAIR mismatch sign for differentiation of IDH-mutant gliomas: a pilot study.

Sci Rep. 2022 Jun;12(1):9197

29.\*Kimura A, Toda Y, Matsumoto Y, Yamamoto H, Yahiro K, Shimada E, Kanahori M, Oyama R, Fukushima S, Nakagawa M, Setsu N, Endo M, Fujiwara T, Matsunobu T, Oda Y, Nakashima Y.

Nuclear  $\beta$ -catenin translocation plays a key role in osteoblast differentiation of giant cell tumor of bone.

Sci Rep. 2022 Aug;12(1):13438

30.\*Kosai-Fujimoto Y, Itoh S, Yugawa K, Fukuhara T, Okuzaki D, Toshima T, Harada N, Oda Y, Yoshizumi T, Mori M.

Impact of JMJD6 on intrahepatic cholangiocarcinoma.

Mol Clin Oncol. 2022 Jun 23;17(2):131

31.\*Kuo YJ, Lewis JS Jr, Truong T, Yeh YC, Chernock RD, Zhai C, Chen YA, Hongo T, Lee CK, Shi Q, Velez Torres JM, Geromes AB, Chu YH, Hsieh MS, Yamamoto H, Weinreb I, Hang JF.

Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract.

Mod Pathol. 2022 Nov;35(11):1587-1595

32.\*Kusafuka K, Sato Y, Nakatani E, Baba S, Maeda M, Yamanegi K, Ueda K, Inagaki H, Otsuki Y, Kuroda N, Suzuki K, Iwai H, Imamura Y, Itakura J, Yamanaka S, Takahashi H, Ito I, Akashi T, Daa T, Hamada M, Yasuda M, Kawata R, Yamamoto H, Tachibana Y, Fukuoka J, Muramatsu A, Arai K, Suzuki M.

The implicated clinical factors for outcomes in 304 patients with salivary duct carcinoma: multi-institutional retrospective analysis in Japan.

Head Neck. 2022 Jun;44(6):1430-1441

33.\*Kusunoki M, Nakayama T, Nishie A, Yamashita Y, Kikuchi K, Eto M, Oda Y, Ishigami K.

A deep learning-based approach for the diagnosis of adrenal adenoma: a new trial using CT.

Br J Radiol. 2022 Jul;95(1135):20211066

34.\*Li L, Irie T, Yoshii D, Komohara Y, Fujiwara Y, Esumi S, Kadohisa M, Honda M, Suzu S, Matsuura T, Kohashi K, Oda Y, Hibi T.  
M-CSFR expression in the embryonal component of hepatoblastoma and cell-to-cell interaction between macrophages and hepatoblastoma.

Med Mol Morphol. 2022 Sep;55(3):236-247

35.\*Maki K, Hata J, Sakata S, Oishi E, Furuta Y, Nakano T, Oda Y, Kitazono T, Ninomiya T.  
Serum uric acid levels and nephrosclerosis in a population-based autopsy study: the hisayama study.

Am J Nephrol. 2022;53(1):69-77

36.\*Matsuno Y, Torisu T, Umeno J, Shibata H, Hirano A, Fuyuno Y, Okamoto Y, Fujioka S, Kawasaki K, Moriyama T, Nagasue T, Zeze K, Hirakawa Y, Kawatoko S, Koga Y, Oda Y, Esaki M, Kitazono T.  
One-year clinical efficacy and safety of indigo naturalis for active ulcerative colitis: a real-world prospective study.

Intest Res. 2022 Apr;20(2):260-268

37.\*Minoda Y, Ihara E, Fujimori N, Nagatomo S, Esaki M, Hata Y, Bai X, Tanaka Y, Ogino H, Chinen T, Hu Q, Oki E, Yamamoto H, Ogawa Y.  
Efficacy of ultrasound endoscopy with artificial intelligence for the differential diagnosis of non-gastric gastrointestinal stromal tumors.

Sci Rep. 2022 Oct;12(1):16640

38.\*Munemura R, Maehara T, Murakami Y, Koga R, Aoyagi R, Kaneko N, Doi A, Perugino CA, Della-Torre E, Saeki T, Sato Y, Yamamoto H, Kiyoshima T, Stone JH, Pillai S, Nakamura S.  
Distinct disease-specific Tfh cell populations in two different fibrotic diseases: IgG4-related disease and Kimura's disease.

J Allergy Clin Immunol. 2022 Aug;150(2):440-455.e17

39.\*Mutaguchi J, Morooka KI, Kobayashi S, Umehara A, Miyauchi S, Kinoshita F, Inokuchi J, Oda Y, Kurazume R, Eto M.  
Artificial intelligence for segmentation of bladder tumor cystoscopic images performed by U-Net with dilated convolution.

J Endourol. 2022 Jun;36(6):827-834

40.\*Nakagawa M, Endo M, Susuki Y, Yokoyama N, Maekawa A, Nabeshima A, Iida K, Fujiwara T, Setsu N, Matsunobu T, Matsumoto Y, Yokoyama R, Yamada Y, Kohashi K, Yamamoto H, Oda Y, Iwamoto Y, Nakashima Y.

Clinical, radiological, and histopathological characteristics of periosteal chondrosarcoma with a focus on the frequency of medullary invasion.

J Clin Med. 2022 Apr;11(7):2062

41.\*Nakano S, Okumura Y, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Kano S, Tsukahara K, Okami K, Kawakita D, Nagao T, Hanai N, Iwai H, Kawata R, Tada Y, Nibu KI, Inagaki H. Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features.

Histopathology. 2022 Mar;80(4):729-735

42.\*Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Taura M, Takeuchi T, Nakagawa T. Real-world experience with pembrolizumab for advanced-stage head and neck cancer patients: a retrospective, multicenter study.

Anticancer Res. 2022 Jul;42(7):3653-3664

43.\*Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Uryu H, Nakashima T, Tamae A, Tanaka R, Taura M, Takeuchi T, Yoshida T, Nakagawa T.

Retrospective study of cisplatin/carboplatin, 5-fluorouracil plus cetuximab (EXTREME) for advanced-stage salivary gland cancer.

In Vivo. Mar-Apr 2022;36(2):979-984

44.\*Negishi T, Matsunobu A, Endo M, Yokoyama R, Kusano S, Furubayashi N, Taguchi K, Shioyama Y, Iida K, Fujiwara T, Setsu N, Matsumoto Y, Nakashima Y, Kohashi K, Yamamoto H, Oda Y, Nakamura M.

An analysis of 20 cases of radiation-associated sarcoma, including 4 cases treated by carbon ion radiotherapy.

Oncology. 2022;100(3):148-154



45.\*Oba U, Kohashi K, Sangatsuda Y, Oda Y, Sonoda KH, Ohga S, Yoshimoto K, Arai Y, Yachida S, Shibata T, Ito T, Miura F.

An efficient procedure for the recovery of DNA from formalin-fixed paraffin-embedded tissue sections.

Biol Methods Protoc. 2022 Jul;7(1):bpac014

46.\*Okugawa K, Yahata H, Hachisuga K, Tomonobe H, Yasutake N, Kodama K, Kenjo H, Yagi H, Ohgami T, Yasunaga M, Onoyama I, Asanoma K, Hori E, Ohishi Y, Oda Y, Kato K.

Evaluation of clinical significance of lymphovascular space invasion in stage IA endometrial cancer.

Oncology. 2022;100(4):195-202

47.\*Okuda S, Ohuchida K, Shindo K, Moriyama T, Kawata J, Tamura K, Sada M, Nagayoshi K, Mizuuchi Y, Ikenaga N, Nakata K, Oda Y, Nakamura M.

Clinical impact of remnant lymphatic invasion on the recurrence of esophageal squamous cell carcinoma after esophagectomy with neoadjuvant chemotherapy.

Oncol Lett. 2022 Aug;24(4):337

48.\*Ono Y, Tagawa T, Kinoshita F, Haratake N, Takada K, Kohno M, Takenaka T, Kamitani T, Shimokawa M, Oda Y, Mori M, Yoshizumi T.

Relationship between consolidation tumor ratio and tumor-infiltrating lymphocytes in small-sized lung adenocarcinoma.

Thorac Cancer. 2022 Aug;13(15):2134-2141

49.\*Otsuji R, Fujioka Y, Hata N, Kuga D, Sangatsuda Y, Takigawa K, Funakoshi Y, Sako A, Yamamoto H, Nakamizo A, Mizoguchi M, Yoshimoto K.

Liquid biopsy with multiplex ligation-dependent probe amplification targeting cell-free tumor DNA in cerebrospinal fluid from patients with adult diffuse glioma.

Neurooncol Adv. 2022 Nov 25;5(1):vdac178

50.\*Shimada E, Matsumoto Y, Nakagawa M, Susuki Y, Endo M, Setsu N, Fujiwara T, Iida K, Nabeshima A, Yahiro K, Kimura A, Hirose T, Kanahori M, Oyama R, Oda Y, Nakashima Y.

Methylation-mediated silencing of protein kinase C zeta induces apoptosis avoidance through ATM/CHK2 inactivation in dedifferentiated chondrosarcoma.

Br J Cancer. 2022 May;126(9):1289-1300

51.\*Shinkawa T, Ohuchida K, Mochida Y, Sakihama K, Iwamoto C, Abe T, Ideno N, Mizuuchi Y, Shindo K, Ikenaga N, Moriyama T, Nakata K, Oda Y, Nakamura M.

Subtypes in pancreatic ductal adenocarcinoma based on niche factor dependency show distinct drug treatment responses.

J Exp Clin Cancer Res. 2022 Mar;41(1):89

52.\*Shinohara S, Bychkov A, Munkhdelger J, Kuroda K, Yoon HS, Fujimura S, Tabata K, Furusato B, Niino D, Morimoto S, Yao T, Itoh T, Aoyama H, Tsuyama N, Mikami Y, Nagao T, Ikeda T, Fukushima N, Harada O, Kiyokawa T, Yoshimi N, Aishima S, Maeda I, Mori I, Yamanegi K, Tsuneyama K, Katoh R, Izumi M, Oda Y, Fukuoka J.

Substantial improvement of histopathological diagnosis by whole-slide image-based remote consultation.

Virchows Arch. 2022 Aug;481(2):295-305

53.\*Shiota M, Fujimoto N, Sekino Y, Tsukahara S, Nagakawa S, Takamatsu D, Abe T, Kinoshita F, Ueda S, Ushijima M, Matsumoto T, Kashiwagi E, Inokuchi J, Uchiumi T, Oda Y, Eto M.

Clinical impact of HSD3B1 polymorphism by metastatic volume and somatic HSD3B1 alterations in advanced prostate cancer.

Andrologia. 2022 Feb;54(1):e14307

54.\*Shirakura T, Yamada Y, Nakata S, Asayama B, Seo Y, Tanikawa S, Kato T, Komoribayashi N, Kubo N, Monma N, Okura N, Tanaka S, Oda Y, Hirato J, Yokoo H, Nobusawa S.

Analysis of clinicopathological features and NAB2-STAT6 fusion variants of meningeal solitary fibrous tumor with ectopic salivary gland components in the cerebellopontine angle.

Virchows Arch. 2022 Dec;481(6):913-923

55.\*Sonoda S, Murata S, Yamaza H, Yuniartha R, Fujiyoshi J, Yoshimaru K, Matsuura T, Oda Y, Ohga S, Tajiri T, Taguchi T, Yamaza T.

Targeting hepatic oxidative stress rescues bone loss in liver fibrosis.

Mol Metab. 2022 Sep;66:101599

56.\*Tabata K, Nishie A, Shimomura Y, Isoda T, Kitamura Y, Nakata K, Yamada Y, Oda Y, Ishigami K, Baba S.

Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[<sup>18</sup>F]-fluoro-2-deoxy-d-glucose positron-emission tomography.

Clin Radiol. 2022 Jun;77(6):436-442

57.\*Tanaka Y, Murata M, Tanegashima K, Oda Y, Ito T.

Nectin cell adhesion molecule 4 regulates angiogenesis through Src signaling and serves as a novel therapeutic target in angiosarcoma.

Sci Rep. 2022 Mar;12(1):4031

58.\*Tanigawa M, Koga Y, Naito Y, Yamaguchi H, Iwasaki T, Kohashi K, Ohike N, Hanada K, Higashi M, Komatsu M, Imai H, Yamakita K, Nagakawa T, Okabe Y, Kato S, Noguchi H, Nakayama T, Yasuda M, Kusano H, Akiba J, Oda Y, Yano H.

Pancreatic hamartoma: detection of harbouring NAB2-STAT6 fusion gene.

Histopathology. 2022 Sep;81(3):319-328

59.\*Tomiya T, Itoh S, Iseda N, Toshida K, Morinaga A, Yugawa K, Fujimoto YK, Tomino T, Kurihara T, Nagao Y, Morita K, Harada N, Kohashi K, Oda Y, Mori M, Yoshizumi T.

Myeloid-derived suppressor cell infiltration is associated with a poor prognosis in patients with hepatocellular carcinoma.

Oncol Lett. 2022 Mar;23(3):93

60.\*Tsukahara S, Shiota M, Takamatsu D, Nagakawa S, Matsumoto T, Kiyokoba R, Yagi M, Setoyama D, Noda N, Matsumoto S, Hayashi T, Contreras-Sanz A, Black PC, Inokuchi J, Kohashi K, Oda Y, Uchiumi T, Eto M, Kang D.

Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine.

Sci Rep. 2022 May;12(1):8535

61.\*Urakami A, Arimura H, Takayama Y, Kinoshita F, Ninomiya K, Imada K, Watanabe S, Nishie A, Oda Y, Ishigami K.

Stratification of prostate cancer patients into low- and high-grade groups using multiparametric magnetic resonance radiomics with dynamic contrast-enhanced image joint histograms.

Prostate. 2022 Feb;82(3):330-344

62.\*Wada N, Fujita N, Ishimatsu K, Takao S, Yoshizumi T, Miyazaki Y, Oda Y, Nishie A, Ishigami K, Ushijima Y.

A novel fast kilovoltage switching dual-energy computed tomography technique with deep learning: Utility for non-invasive assessments of liver fibrosis.

Eur J Radiol. 2022 Oct;155:110461

63.\*Yagita K, Noguchi H, Koyama S, Hamasaki H, Komori T, Aishima S, Kosaka T, Ueda M, Komohara Y, Watanabe A, Sasagasako N, Ninomiya T, Oda Y, Honda H.

Chronological changes in the expression pattern of hippocampal prion proteins during disease progression in sporadic creutzfeldt-Jakob disease MM1 subtype.

J Neuropathol Exp Neurol. 2022 Oct;81(11):900-909

64.\*Yahata H, Kodama K, Okugawa K, Hachisuga K, Yasutake N, Maenohara S, Yagi H, Yasunaga M, Ohgami T, Onoyama I, Asanoma K, Kobayashi H, Sonoda K, Baba S, Ishigami K, Ohishi Y, Oda Y, Kato K.

Long-term follow up after sentinel node biopsy alone for early-stage cervical cancer.

Gynecol Oncol. 2022 Apr;165(1):149-154

65.\*Yamaguchi K, Yoshihiro T, Ariyama H, Ito M, Nakano M, Semba Y, Nogami J, Tsuchihashi K, Yamauchi T, Ueno S, Isobe T, Shindo K, Moriyama T, Ohuchida K, Nakamura M, Nagao Y, Ikeda T, Hashizume M, Konomi H, Torisu T, Kitazono T, Kanayama T, Tomita H, Oda Y, Kusaba H, Maeda T, Akashi K, Baba E.

Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model.

Gastric Cancer. 2022 Sep;25(5):862-878

66.\*Yasutake N, Iwasaki T, Yamamoto H, Sonoda K, Kodama K, Okugawa K, Asanoma K, Yahata H, Kato K, Oda Y.

Cyclin-dependent kinase 8 is an independent prognosticator in uterine leiomyosarcoma.

Pathol Res Pract. 2022 Jul;235:153920

67.\*Yoshimaru K, Miyoshi K, Kinoshita Y, Obata S, Yanagi Y, Takahashi Y, Kajihara K, Irie K, Uchida Y, Toriigahara Y, Kawano Y, Kohashi K, Yoshioka T, Nakazawa A, Matsuura T, Oda Y, Tajiri T, Taguchi T.

Immunohistochemistry reveals an increased number of ganglion cells in the normal-size plexus, as a pathological feature of immaturity of ganglia.

Comp Clin Path. 2022 Nov;31(6):951-957

68.\*Yoshimaru K, Tamaki A, Matsuura T, Kohashi K, Kajihara K, Irie K, Hino Y, Uchida Y, Toriigahara Y, Kawano Y, Shirai T, Oda Y, Tajiri T, Taguchi T.

Palisading-like arrangement of immature ganglion cell in myenteric ganglia is a unique pathological feature of immaturity of ganglia.

J Pediatr Surg. 2022 Jul;57(7):1269-1273

69.\*Yoshimaru K, Yamaza T, Kajioka S, Sonoda S, Yanagi Y, Matsuura T, Yoshizumi J, Oda Y, Iwata N, Takai C, Nakayama S, Taguchi T.

Dental pulp stem cells as a therapy for congenital entero-neuropathy.

Sci Rep. 2022 Apr;12(1):6990